Colorectal Cancer Clinical Trials in Houston, Texas

49 studies are recruiting for colorectal cancer in Houston, Texas right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies, page 2

1. Regorafenib (Reg) and Lorigerlimab (Lor), RELO Regimen, in Treatment of High-risk Patients With Colorectal Cancer With Radiographic Occult Molecular Residual Disease After End of Established Definitive Therapy [ReLOAD Trial]

   To learn about the effects of the drugs regorafenib and lorigerlimab on circulating tumor DNA (ctDNA) in patients with CRC and who have radiographic occult minimal residual disease (MRD) after completing standard-of-care therapy

   Stage

   Phase 2

   Ages

   18 and older

   Site

   MD Anderson Cancer Center, Houston, Texas

   Run by

   M.D. Anderson Cancer Center

   See if you can join NCT07071961 on ClinicalTrials.gov

2. Trial of AMB-05X for Patients With ctDNA(+) Colorectal Cancer After Curative-intent Treatment

   To investigate the efficacy of AMB-05X in patients with CRC with MRD as determined by a ctDNA(+) blood test and no clinically detectable radiographic disease.

   Stage

   Phase 2

   Ages

   18 and older

   Site

   The University of Texas MD Anderson Cancer Center, Houston, Texas

   Run by

   M.D. Anderson Cancer Center

   See if you can join NCT06617858 on ClinicalTrials.gov

3. A Study of MRG007 (ARR-217) in Patients With Advanced Solid Tumors

   This is an open-label, multi-center, phase I study to evaluate the safety, tolerability, efficacy, and pharmacokinetics of MRG007 (ARR-217) in patients with unresectable locally advanced or metastatic solid tumors.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   MD Anderson Cancer Center, Houston, Texas

   Locations

   21 in total

   Run by

   ArriVent BioPharma, Inc.

   See if you can join NCT07066657 on ClinicalTrials.gov

4. A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors

   This is an open label, multicenter, phase 1/2 study to assess the safety/tolerability and preliminary clinical activity of STAR0602 as a single agent and in combination with chemotherapy administered intravenously in participants with advanced solid tumors that are antigen-rich.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   The University of Texas, MD Anderson Cancer Center, Houston, Texas

   Locations

   19 in total

   Run by

   Marengo Therapeutics, Inc.

   See if you can join NCT05592626 on ClinicalTrials.gov

5. Connecting Black Families in Houston, Texas to Hereditary Cancer Genetic Counseling, Genetic Testing, and Cascade Testing by Using a Simple Genetic Risk Screening Tool and Telegenetics

   To identify Black individuals who are eligible for genetic testing through trusted community organizations, and to connect Black individuals and their families to genetic testing and counseling so that they can know their cancer risk and how to decrease it.

   Stage

   Not phased

   Ages

   18 and older

   Site

   MD Anderson Cancer Center, Houston, Texas

   Run by

   M.D. Anderson Cancer Center

   See if you can join NCT05694559 on ClinicalTrials.gov

6. Safety and Effectiveness Evaluation of the COLO-BT as an Alternative Treatment to the Ileostomy

   The purpose of this study is to evaluate the Colorectal Balloon Tube (hereinafter referred to as COLO-BT™) device, a single use, temporary intraluminal bypass device, intended to reduce contact of fecal content with an anastomotic site, following colorectal surgery (open or laparoscopic)

   Stage

   Not phased

   Ages

   19 to 80

   Site

   Baylor College of Medicine, Houston, Texas

   Locations

   3 in total

   Run by

   JSR Medical Co., Ltd.

   See if you can join NCT05826743 on ClinicalTrials.gov

7. IDOV-Immune for Advanced Solid Tumors

   This is a Phase I clinical trial evaluating an investigational treatment called IDOV-Immune, a type of oncolytic virus therapy, for adults with advanced solid tumors that have not responded to standard treatments. Oncolytic viruses are designed to infect and destroy cancer cells and have the potent…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   MD Anderson Cancer Center, Houston, Texas

   Locations

   5 in total

   Run by

   ViroMissile, Inc.

   See if you can join NCT06910657 on ClinicalTrials.gov

8. Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers

   The purpose of this study is to evaluate the safety, tolerability, dosimetry and preliminary efficacy of [177Lu]Lu-NNS309 and the safety, dosimetry and imaging properties of [68Ga]Ga-NNS309 in patients aged ≥ 18 years with locally advanced or metastatic pancreatic ductal adenocarcinoma (PDAC), non-…

   Stage

   Phase 1

   Ages

   18 to 100

   Site

   Uni Of TX MD Anderson Cancer Cntr, Houston, Texas

   Locations

   29 in total

   Run by

   Novartis Pharmaceuticals

   See if you can join NCT06562192 on ClinicalTrials.gov

9. Study of Orally Administered MOMA-341 in Participants With Advanced or Metastatic Solid Tumors

   This Phase 1, multi-center, open-label, dose escalation and dose optimization study is designed to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PDx), and preliminary clinical activity of MOMA-341 administered orally as a single agent or combination therapy in patients w…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Investigative Site #129, Houston, Texas

   Locations

   15 in total

   Run by

   MOMA Therapeutics

   See if you can join NCT06974110 on ClinicalTrials.gov

10. A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid Tumors

    The purpose of this study is to learn about the safety and effects of the study medicine when given alone or together with other anti-cancer therapies. Anti-cancer therapy is a type of treatment to stop the growth of cancer. This study also aims to find the best amount of study medication. This stu…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    The University of Texas - M.D. Anderson Cancer Center, Houston, Texas

    Locations

    13 in total

    Run by

    Pfizer

    See if you can join NCT07318805 on ClinicalTrials.gov

11. A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors

    The purpose of this study is to evaluate the efficacy and safety of zanidatamab for the treatment of participants with previously treated solid tumors that have Human Epidermal Growth Factor Receptor 2 (HER2) Immunohistochemistry (IHC) 3+ overexpression.

    Stage

    Phase 2

    Ages

    18 and older

    Site

    MD Anderson Cancer Center, Houston, Texas

    Locations

    28 in total

    Run by

    Jazz Pharmaceuticals

    See if you can join NCT06695845 on ClinicalTrials.gov

12. A Trial to Evaluate the Safety and Activity of Fruquintinib in Minority Populations With Advanced, Previously Treated Colorectal Cancer

    High blood pressure (hypertension) is a known side effect of the treatment with fruquintinib. Current research does not provide a clear answer whether minority groups such as Black/African American and/or Hispanic/Latino with refractory metastatic colorectal cancer (mCRC) have a bigger risk of high…

    Stage

    Phase 4

    Ages

    18 and older

    Site

    Oncology Consultants - Memorial City Location, Houston, Texas

    Locations

    45 in total

    Run by

    Takeda

    See if you can join NCT06562543 on ClinicalTrials.gov

13. Initial Safety of SFM Plus OTOLoc for Creating Side-to-side or End-to-side Colorectal Anastomoses

    The primary objective of this trial is to investigate the safety and effectiveness of the Flexagon 25mm SFM system plus OTOLoc when used to create a side-to-side Ileo-colic, Colo-colonic and side-to-side or end-to-side colorectal anastomoses in participants undergoing colon surgery. This will be ev…

    Stage

    Not phased

    Ages

    22 and older

    Site

    University of Texas Health Science Center, Houston, Texas

    Locations

    2 in total

    Run by

    GI Windows, Inc.

    See if you can join NCT07276529 on ClinicalTrials.gov

14. A Study to Investigate ALE.P03 as Monotherapy in Adult Patients With Selected Advanced or Metastatic CLDN1+ Solid Tumors

    The purpose of this study is to evaluate the safety, tolerability, pharmacokinetic, pharmacodynamic, preliminary anti-tumor activity, and to determine the recommended Phase II dose (RP2D) of the ALE.P03 monotherapy in adult patients with selected squamous solid tumors.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    MD Anderson Cancer Center, Houston, Texas

    Locations

    41 in total

    Run by

    Alentis Therapeutics AG

    See if you can join NCT07169734 on ClinicalTrials.gov

15. A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types

    This is a Phase 1a/1b, open-label, multicenter dose escalation and dose expansion clinical study to evaluate the safety, PK, immunogenicity and preliminary efficacy of IDE034 in participants with locally advanced/metastatic solid tumor types that express B7-H3 and PTK7.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    MD Anderson, Houston, Texas

    Locations

    15 in total

    Run by

    IDEAYA Biosciences

    See if you can join NCT07503808 on ClinicalTrials.gov

16. Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions

    This is a Phase 1/2, multi-center, open-label basket study designed to evaluate the safety and anti-tumor activity of IDE196 in patients with solid tumors harboring GNAQ or GNA11 (GNAQ/11) mutations or PRKC fusions, including metastatic uveal melanoma (MUM), cutaneous melanoma, colorectal cancer, a…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    The University of Texas MD Anderson Cancer Center, Houston, Texas

    Locations

    15 in total

    Run by

    IDEAYA Biosciences

    See if you can join NCT03947385 on ClinicalTrials.gov

17. A Phase IIa Randomized, Double-Blinded Clinical Trial of Naproxen or Aspirin for Cancer Immune Interception in Lynch Syndrome

    To learn about the effects of naproxen and aspirin on the normal colon in people with Lynch Syndrome.

    Stage

    Phase 2

    Ages

    18 and older

    Site

    MD Anderson Cancer Center, Houston, Texas

    Run by

    M.D. Anderson Cancer Center

    See if you can join NCT05411718 on ClinicalTrials.gov

18. A Study to Determine the Effect of CT3001 in Patients With Advanced Solid Tumors

    This is an FIH, multicenter, open-label, dose escalation and dose expansion/dose optimization study of CT3001, which will be conducted in 2 phases: Phase 1 and Phase 2b. Phase 1 will be a standard 3+3 dose escalation and dose finding study in patients with advanced solid tumors for whom there is no…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    MD Anderson Cancer Center, Houston, Texas

    Run by

    Crossignal Therapeutics, Inc.

    See if you can join NCT06598007 on ClinicalTrials.gov

19. Identifying Underserved Individuals inTexas With Hereditary Cancer Risk Using Mobile Mammography Units and Telegenetics.

    Identifying women at risk for hereditary cancer potentiates prevention, early detection or personalised treatment against cancer. We using mobile mammography units will provide genetic sceening and testing services to underserved women coming for thier mammograms to these units.

    Stage

    Not phased

    Ages

    18 and older

    Site

    M D Anderson Cancer Center, Houston, Texas

    Run by

    M.D. Anderson Cancer Center

    See if you can join NCT05649072 on ClinicalTrials.gov

20. Precision-MRD: Prospective Observational Study of Biomarker-directed Systemic Therapy for Colorectal Cancer Patients With Minimal Residual Disease

    The goal of this clinical research study is to learn about the effects of biomarkertargeted therapy on ctDNA in patrticipants with CRC and MRD. This is an observational study. Participants will be monitored while receiving biomarker-directed therapy that is determined by your treating oncologist (c…

    Stage

    Not phased

    Ages

    18 and older

    Site

    MD Anderson Cancer Center, Houston, Texas

    Run by

    M.D. Anderson Cancer Center

    See if you can join NCT06878131 on ClinicalTrials.gov

21. A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy

    This study is an open-label Phase Ib (Part A) dose escalation followed by a blinded, randomized, multi cohort Phase 2a (Part B) comparison of combination vs. reference regimens. Currently study will only be enrolling the Phase 1b and the Phase 2a protocol requirements will be added to the study nea…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    MD Anderson Cancer Center, Houston, Texas

    Locations

    5 in total

    Run by

    7 Hills Pharma, LLC

    See if you can join NCT06362369 on ClinicalTrials.gov

22. A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies

    This is a two-part, open-label, multicenter, dose escalation and dose expansion study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PDx), and anti- tumor activity of ETX-19477, a novel reversible small molecule inhibitor of PARG.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    MD Anderson Cancer Center, Houston, Texas

    Locations

    14 in total

    Run by

    858 Therapeutics, Inc.

    See if you can join NCT06395519 on ClinicalTrials.gov

23. Binary Oncolytic Adenovirus in Combination With HER2-Specific Autologous CAR VST, Advanced HER2 Positive Solid Tumors

    This study is a first in human Phase 1 study that involves patients with a type of cancer called HER2 (Human Epidermal Growth Factor Receptor 2) positive cancer. This study asks patients to volunteer to take part in a research study investigating the safety and efficacy of using special immune cell…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Baylor St. Luke's Medical Center, Houston, Texas

    Run by

    Baylor College of Medicine

    See if you can join NCT03740256 on ClinicalTrials.gov

24. A Study of IBI363 in Subjects with Advanced Solid Malignancies

    This is a Phase 2, open-label, multicenter study designed to evaluate the efficacy, safety and tolerability of IBI363 (study drug) in subjects with advanced, refractory solid malignancies.

    Stage

    Phase 2

    Ages

    18 and older

    Site

    MD Anderson Cancer Center-University of Texas, Houston, Texas

    Locations

    9 in total

    Run by

    Innovent Biologics (Suzhou) Co. Ltd.

    See if you can join NCT06281678 on ClinicalTrials.gov